Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...

In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...

After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo looks to win the market ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical ...

After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite ...